Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pfizer Japan: Sales Up 2.6% despite Fall in Sales of Norvasc
March 15, 2010
- Premium Will Be Effective for Expediting Development of New Drugs, Indications: Mr Nagatsuma
March 15, 2010
- Shionogi Licenses Ospemifene from QuatRx
March 15, 2010
- Toyobo's Sales to Top ¥400 Bil. in FY2015 Driven by Life Science Business
March 15, 2010
- Korosho Starts Hearing Major Chain Pharmacy Operators
March 15, 2010
- EFPIA Japan to Work to Eliminate Drug Lag
March 15, 2010
- Astellas Withdraws Application for Diabetic Incipient Nephropathy for Micardis
March 15, 2010
- Teijin Licenses SB623 from SanBio
March 15, 2010
- Korosho to Prepare for 2nd Round of Screening by GRU
March 15, 2010
- 2009 Sales of Ethical Drugs Up 7.2% to ¥8,851.6 Bil.: IMS Japan
March 15, 2010
- Takeda to Initiate PIII Trials for Lu AA21004, Lu AA24530 in the US
March 15, 2010
- Banyu, Santen to Copromote Cosopt
March 15, 2010
- Sanofi-aventis Begins Post-marketing Program on Apidra
March 15, 2010
- Kyowa Kirin, Solasia Sign License Agreement for Sancuso in Asia
March 15, 2010
- Eli Lilly, Merck, Pfizer to Jointly Create Cancer DB in Asia
March 15, 2010
- NanoCarrier to Obtain Process Patent on NC-4016 in the US
March 15, 2010
- SymBio Begins PII Trial of Bendamustine for Aggressive NHL
March 15, 2010
- Tsumura to Procure Raw Materials for Kampo Medicines in Laos
March 15, 2010
- JCPM to Provide e-Learning Programs for Clinical Trials
March 15, 2010
- Mr Matsumura of Terumo Calls For Regulatory Reform of Medical Devices
March 15, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…